Hepion Pharmaceuticals Inc
0.1958 %
-86.97 %
Yet to be announced
Company Overview
Hepion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of liver diseases. Their lead drug candidate, rencofilstat (CRV431), is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The company is currently in clinical trials and does not yet generate revenue from product sales.
Revenue Sources
PassHepion Pharmaceuticals is a pre-revenue biotechnology company focused on developing treatments for liver diseases. As the company has not yet commercialized any products and reports zero revenue across all examined quarters, this criterion is not applicable at this stage of the company's development.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
The company shows minimal to no interest expense across the examined quarters, with only USD 4,349 reported in Q1 2024 and zero in other quarters. Given that the company is pre-revenue and still in R&D phase, the interest expense check is not material to its business model at this stage.
Operational Ethics
PassBased on review of company filings and public information, there is no evidence of any significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party. The company's operations and clinical trials appear to be primarily conducted in the United States.
Comments